Ginkgo Bioworks (DNA) Notes Receivable Fair Value Disclosure — Quarterly & Annual

Screener

Notes Receivable Fair Value Disclosure at other companies

UMH

UMH PropertiesUMH

$1.6M-15.8%

Priority Technology HoldingsPRTH

$22.7M+127%

Ginkgo BioworksDNA

$7.13M—

Universal Technical InstituteUTI

$52.15M—

F&G Annuities & LifeFG

$0-100%

Marcus & MillichapMMI

$5.77M—

Other financials

Income statement

Revenue$20.2M-48.5%

Gross profit$18.4M-45.4%

Operating income-$58.5M-0.7%

Net income-$46.7M+22.5%

EPS (diluted)-$1.42+27.6%

Balance sheet

Cash & equivalents$172.0M-31.6%

Total debt$404.1M-5.8%

Total equity$420.3M-31.4%

Total assets$990.0M-19.6%

Cash flow

Operating cash flow-$44.3M-10.0%

CapEx$2.6M+6,792%

Free cash flow-$46.9M-16.4%

Valuation

Market cap$612.09M-25.1%

Enterprise value$844.19M-15.1%

P/S5.5×+1.6×

Profitability

Gross margin91.8%—

Operating margin-259.9%+1,304pp

Net margin-260%+718pp

FCF margin-156.3%+38.7pp

Returns & leverage

Return on equity-56.3%+23.1pp

Debt / equity1×+0.3×

Current ratio4.6×-0.8×

Where this comes from

Reported directly by Ginkgo Bioworks in its filing.

Tagged under the XBRL concept us-gaap:NotesReceivableFairValueDisclosure.

The source filing: Ginkgo Bioworks’s 10-Q, filed August 6, 2026. Open the filing →

Filed: Aug 6, 2026, 4:09 PM EDT
Fiscal quarter: Q2 FY2026
Calendar quarter: Q2 2026
Accession: 0001628280-26-054298

FAQ

What is Ginkgo Bioworks's notes receivable fair value disclosure?: Ginkgo Bioworks (DNA) reported notes receivable fair value disclosure of $7.13M in Q4 2025.
What does notes receivable fair value disclosure mean?: Notes Receivable Fair Value Disclosure as reported by Ginkgo Bioworks Holdings, Inc..

Ask your AI about Ginkgo Bioworks's notes receivable fair value disclosure.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk